Novel high-throughput screening system for cancer therapy with simultaneous combination treatments

J. Y. Kim, D. Taylor, Kaushal Rege, H. S. Kim, A. R. Han, A. Jayaraman

Research output: Chapter in Book/Report/Conference proceedingConference contribution

1 Scopus citations

Abstract

In this paper, we report the development of a microfluidic high-throughput screening system for high-throughput screening of drug molecule interactions on cancer cell death. A key feature is that 64 pair-wise concentrations (between eight concentrations of two drugs) are generated using a traditional diffusive microfluidic mixer and a time-dependent variable concentration mixer. Using this novel high-throughput combination array, we generated pair-wise combinations of the cancer drug sensitizer doxorubicin and the cytokine TRAIL, and used it for on-chip screening against PC3 prostate cancer cells. Our results identify a concentration range where doxorubicin and TRAIL are synergistic and demonstrates the utility of the system as a high-throughput anti-cancer drug screening tool.

Original languageEnglish (US)
Title of host publication14th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2010, MicroTAS 2010
Pages836-838
Number of pages3
StatePublished - 2010
Event14th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2010, MicroTAS 2010 - Groningen, Netherlands
Duration: Oct 3 2010Oct 7 2010

Publication series

Name14th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2010, MicroTAS 2010
Volume2

Other

Other14th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2010, MicroTAS 2010
Country/TerritoryNetherlands
CityGroningen
Period10/3/1010/7/10

Keywords

  • Combination treatment
  • Doxorubicin
  • High-throughput screening
  • Prostate cancer
  • TRAIL

ASJC Scopus subject areas

  • Control and Systems Engineering

Fingerprint

Dive into the research topics of 'Novel high-throughput screening system for cancer therapy with simultaneous combination treatments'. Together they form a unique fingerprint.

Cite this